PA5-79966

antibody from Invitrogen Antibodies

Targeting: SDHC CYB560, cybL, PGL3

Western blot (Supportive data in Antibodypedia)

Immunohistochemistry (Data presented on provider website)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-79966

Provider

Invitrogen Antibodies

Product name

SDHC Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Synthetic peptide

Description

Reconstitute with 0.2 mL of distilled water to yield a concentration of 500 µg/mL.

Reactivity

Human, Mouse, Rat

Host

Rabbit

Isotype

IgG

Vial size

100 µg

Concentration

500 µg/mL

Storage

-20°C

References

Submitted references

Genome-wide CRISPR/Cas9 deletion screen defines mitochondrial gene essentiality and identifies routes for tumour cell viability in hypoxia.

Thomas LW, Esposito C, Morgan RE, Price S, Young J, Williams SP, Maddalena LA, McDermott U, Ashcroft M
Communications biology 2021 May 21;4(1):615

Western blot

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot analysis of SDHC in Lane 1: rat liver tissue lysate, Lane 2: mouse liver tissue lysate, Lane 3: HeLa whole cell lysate using 40-50 µg per well. Sample was incubated with SDHC (Product # PA5-79966) at a dilution of 0.5 µg/mL.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot analysis of SDHC in Lane 1: rat liver tissue lysate, Lane 2: mouse liver tissue lysate, Lane 3: HeLa whole cell lysate using 40-50 µg per well. Sample was incubated with SDHC (Product # PA5-79966) at a dilution of 0.5 µg/mL.

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Fig. 3 Loss of SDHC improves tumour cell growth in hypoxia. a Chart shows all genes with significantly enriched sgRNAs (robust rank aggregation (RRA) score, positive) in hypoxia-glucose at different FDR thresholds. b Chart shows relative growth of U2OS cells cultured for 5 days in normoxia or hypoxia (1% O 2 ) treated with non-targeting control siRNA (siCtrl) or siRNA targeting SDHC (siSDHC). n = 3. Mean +- S.D. ; n.s. not significant; *** p < 0.001. c Western blots show expression of SDHC, and BNIP3 in U2OS cells incubated for 5d in normoxia (Nor) or hypoxia (Hyp, 1% O 2 ). beta-Actin used as a loading control. d Chart shows the relative density of SDHC bands from samples in ( c ). n = 3; mean +- S.D. ; ** p < 0.01. e Charts show expression of SDHC and EGLN3 from U2OS cells incubated for 5d in normoxia or hypoxia (1% O 2 ). n = 3; mean +- S.D. ; ** p < 0.01. f Charts show relative growth of U2OS cells incubated for 5d in normoxia or hypoxia (1% O 2 ), in the presence of 25 mM galactose, treated with non-targeting control siRNA (siCtrl) or siRNA targeting SDHC (siSDHC). n = 3; mean +- S.D. ; n.s. not significant; * p < 0.05; ** p < 0.01.